Trial · NCT02036918
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | anti-PA2024 immune response in lymph node-derived leukocytes | Lymph node biopsy, approximately 10 weeks | Proportion of patients with lymph node-derived leukocytes showing anti-PA2024 activity as measured by IFNγ ELISPOT |
| Primary | anti-PAP immune response in lymph node-derived leukocytes | Lymph node biopsy, approximately 10 weeks | Proportion of patients with lymph node-derived leukocytes showing anti-PAP activity as measured by IFNγ ELISPOT |
| Primary | anti-PA2024 immune response in PBMCs | Baseline | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | Baseline | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | Prior to sipuleucel-T infusion 2, approximately 6 weeks | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | Prior to sipuleucel-T infusion 2, approximately 6 weeks | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | Prior to sipuleucel-T infusion 3, approximately 8 weeks | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | Prior to sipuleucel-T infusion 3, approximately 8 weeks | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | 2 weeks after the last sipuleucel-T infusion | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | 2 weeks after the last sipuleucel-T infusion | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | 3 months post-treatment | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | 3 months post-treatment | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | 6 months post-treatment | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | 6 months post-treatment | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Secondary | Serum anti-PA2024 antibody level | Baseline, up to 6 months post-treatment | Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation |
| Secondary | serum anti-PAP antibody level | Baseline, up to 6 months post-treatment | Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02036918/registered